Is the Demonstration of Adenoma Reduction With Rofecoxib a Pyrrhic Victory?

Gastroenterology

Volumn 131, Issue 6, 2006, Pages 2003-2005

  Lynch, Patrick M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; FLUOROURACIL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

CANCER PREVENTION; CANCER RESEARCH; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; DEATH; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOSIS;

EID: 33845655380     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.10.052     Document Type: Editorial

References (16)

1. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., and Willett W.C. Aspirin use and the risk for colorectal and adenoma in male health professionals. Ann Intern Med 121 (1994) 241-246
2. Chan A.T., Giovannucci E.L., Schernhammer E.S., Colditz G.A., Hunter D.J., Willett W.C., and Fuchs C.S. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern 140 (2004) 157-166 Med
3. Cook N.R., Lee I.-M., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., Hennekens C.H., and Buring J.E. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (2005) 47-55
4. Baron J., Sandler R.S., and Bresalier R.S. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 (2006) 1674-1682
5. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D., Hess T.M., Woloj G.M., Boisserie F., Anderson W.F., Viner J.L., Bagheri D., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzburg B., Sylwestrowicz T., Gordon J.B., Hawk E.T., and APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884
6. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B., and PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
7. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomized trials. BMJ 332 (2006) 1302-1308
8. Psaty B.M., and Potter J.D. Risks and benefits of celecoxib to prevent recurrent adenomas. [editorial]. N Engl J Med 355 (2006) 950-952
9. Zhang J., Ding E.L., and Song Y. Adverse effects of cyclooxygenase inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296 (2006) 1619-1632
10. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
11. Graham D.J. Cox-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. [editorial]. JAMA 296 (2006) 1653-1656
12. Steinbach G., Lynch P.M., Phillips R.K.S., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimara T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
13. Peterson S.K., Watts B.G., McGivern B., Burke S., Latchford A., Phillips R., Burke C., Church J., Hasson H., and Lynch P.M. FAP-affected adults' responses to reported cardiovascular risks associated with celecoxib (2005) Presented at Collaborative Group of the Americas on Inherited Colon Cancer (CGA), Salt Lake City, Utah, October
14. Burke C., Hawk E., Eagle C., Woloj M., Church J., Hasson H., Patterson S., Benfield R., Half E., Miller D., Ayers G.D., and Lynch P. Design and primary safety outcome in a phase I trial of celecoxib in children with FAP. Abstract P29. Familial Cancer 4 Supp1 (2005) 77
15. Lynch P., Burke C., Hawk E., Eagle C., Woloj M., Church J., Hasson H., Patterson S., Benfield R., Half E., Miller D., and Ayers G.D. Colonoscopy in a phase I safety trial of celecoxib in children with FAP. Abstract F42. Familial Cancer 4 Supp1 (2005) 57
16. Information on clinical trials and human research studies (2006). http://www.clinicaltrials.gov/ Available: www.clinicaltrials.gov/. Accessed October 16